Table 1.

Studies of the effects current hypolipidemic regimens exert on NETs and NETosis.

Authors	Year	Type of Study	Results
Chow et al. [85]	2010	Experimental	Mevastatin, lovastatin, simvastatin, fluvastatin enhance NETs production of human neutrophils in vitro.
Kessinger et al. [83]	2015	Experimental	Atorvastatin compared to PBS reduced levels of neutrophils and CitH3 in murine thrombi.
Al-Ghoul et al. [84]	2014	Experimental	Simvastatin exerted protective effect against inflammation and systemic NETosis post-thermal injury.
Liu et al. [88]	2014	Experimental	Pretreatment with atorvastatin alleviated the cholesterol-induced NETs production in vitro.
Park et al. [89]	2018	Clinical	NETosis biomarkers (NE, DNA–histone complexes, cell-free DNA) levels decreased non-significantly after 3 month treatment with moderate intensity statins in 25 diabetic patients.
Wang et al. [93]	2017	Experimental	NETs formation and leucocyte accumulation significantly reduced in PCSK9 -/- mice compared to wild-type controls.
De Vries et al. [90]	2022	Clinical	Attenuation of plasma NETosis components association with atherosclerotic plaque vulnerability index probably via effects in NETs levels or functions.
Henneck et al. [86]	2022	Experimental	Simvastatin and mevastatin trigger NETs formation in isolated neutrophils by depleting intracellular cholesterol independently from oxygen supply.
Sapey et al. [91]	2019	Clinical	Add-on high dose simvastatin versus placebo on 62 patients with community-acquired pneumonia with sepsis reduced NETosis on treatment day 4.
Chen et al. [92]	2023	Experimental	Simvastatin reduced NETs formation in bronchoalveolar lavage and lung tissue in a murine model of severe asthma.